Clinical Trial Update: Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for MEDI-522 (Abergrin) in patients with advanced malignant melanoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• MEDI-522 (Abergrin) (MEDI-522)

Snippet

Sponsor: MedImmune LLC | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED